Theratechnologies Inc (TSE:TH)‘s stock had its “sector perform market weight” rating reaffirmed by equities researchers at National Bank Financial in a research note issued to investors on Tuesday.
Several other equities analysts have also recently issued reports on TH. Canaccord Genuity reduced their price objective on Theratechnologies from C$4.25 to C$3.75 in a report on Thursday, July 7th. Mackie cut their price target on Theratechnologies from C$5.30 to C$4.40 in a report on Wednesday, July 6th.
Theratechnologies (TSE:TH) traded up 4.63% during trading on Tuesday, reaching $2.94. The company had a trading volume of 62,118 shares. The company has a market capitalization of $193.84 million and a P/E ratio of 735.00. The firm’s 50 day moving average is $2.65 and its 200-day moving average is $2.48. Theratechnologies has a 12 month low of $1.26 and a 12 month high of $3.74.
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.